A randomized, phase III, multi-national study, presented at fourth annual Genitourinary Cancers Symposium, being held February 2-4, 2012, at the San Francisco Marriott Marquis in San Francisco, CA, USA, shows that a novel radiation-emitting agent that targets bone – and aimed at treating bone metastases – both improved survival and delayed cancer-related bone problems in men with metastatic castration-resistant prostate cancer (CRPC). The agent, radium-223 chloride or Ra-223…
Contributor
More from this contributor
- Blinatumomab Achieved High Rate ...
- Fidaxomicin Offers Faster Diarrh...
- Rilotumumab Moves into Phase III...
- Study Shows ImmunoSEQ Assay Sign...
Comments
To add a comment to the original post, click here.
You must be signed in to post a comment.
Sign in nowThere are no comments for this post.